News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘OvarianCancer’ clear

  • One of the shortcomings of a therapy that uses millions of identical antibodies to boost the immune system's attack on cancer cells is that many patients whose tumors recede in response to the treatment also experience serious inflammatory problems, such as severe diarrhea and rashes. In a new study, a team led by Dana-Farber Cancer Institute researchers shows that giving periodic infusions of such "monoclonal" antibodies to patients who have received a widely used cancer vaccine unleashes a strong immune response to tumors, with less-harsh side effects.

Tags: Melanoma, OvarianCancer, TargetedTherapy

  • Ursula Matulonis, MD, director of the Gynecologic Oncology Program in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, says there are three things that every woman should know about ovarian cancer — known as the silent killer.

Tags: OvarianCancer, GynecologicCancers

  • Dana-Farber researchers find novel antibody-guided drug achieves responses in platinum drug-resistant ovarian cancer.

Tags: OvarianCancer, GynecologicCancers

  • A new study that proposes a three-in-one test for gynecologic cancers underscores the promise of molecular screening for early detection of endometrial and ovarian cancers, but also suggests that such tests are not yet ready for clinical use. Andrea Myers, MD, PhD, a co-author of the commentary on the study, says the test is an important step in that direction.

Tags: CervicalCancer, OvarianCancer, Prevention, GynecologicCancers

  • Dana-Farber/Brigham and Women's Cancer Center and the Massachusetts Ovarian Cancer Awareness Coalition want women to get the facts and recognize the signs of the disease.

Tags: OvarianCancer, GynecologicCancers

  • Dana-Farber scientists identify a genetic flaw that drives some ovarian cancers, which could assist in identifying treatments for ovarian cancer patients.

Tags: Genomics, OvarianCancer, GynecologicCancers

  • Research led by Dana-Farber Cancer Institute scientists may soon enable doctors to determine which patients with the most common form of ovarian cancer – high-grade serous ovarian cancer (HGSOC) – are most likely to benefit from a certain class of drugs.

Tags: OvarianCancer, GynecologicCancers

  • The discovery of a subtype of ovarian cancer that could account for up to one-third of all serous ovarian cancers may lead to clinical trials using anti-angiogenic drugs that are already being tested in other cancers.

Tags: OvarianCancer, GynecologicCancers

  • As part of Project Achilles, aimed at finding the "Achilles heel" of cancer, researchers from Dana-Farber Cancer Institute, Harvard and the Broad Institute of MIT examined cells from over 100 tumors, including 25 ovarian cancer tumors, finding promising new targets for genetic research.

Tags: BasicResearch, OvarianCancer, GynecologicCancers

  • On Sept. 6 at Boston City Hall Plaza, Dana-Farber/Brigham and Women's Cancer Center, along with a coalition of six organizations, launched a month-long campaign to promote ovarian cancer awareness. The group, known as OvarianCancerAwareness.org, is dedicated to educating the public about the subtle symptoms of ovarian cancer to promote early detection.

Tags: OvarianCancer

Showing 1-10 of 21 items